Brief: AIM Vaccine Says Pre-Applications For Clinical Trials Submitted To US FDA
29/08/2024 15:12
Aug 29 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* PRE-APPLICATIONS FOR CLINICAL TRIALS FOR MRNA RSV & MRNA
SHINGLES/HERPES ZOSTER VACCINES OF AIM VACCINE SUBMITTED TO US
FDA
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine